Article title: Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management
Authors: O’Connor L, Carbone S, Gobbo A, et al.
Journal: EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Bibliometrics: Volume 16, Number 09, pages 799-812
DOI: https://doi.org/10.1080/17512433.2023.2249414
When this article was published in an issue, there were some errors in the text, which is now corrected as below.
In section 3.2, the statement
“The amphetamine transdermal system (patch) carries the same warnings as other formulations in the amphetamine class: serious cardiovascular reactions, blood pressure and heart rate increases, psychiatric symptoms including mania and psychosis, suppression of growth, peripheral vasculopathy including Raynaud’s phenomenon, serotonin syndrome, contact sensitization, application site reactions, external heat increases both the rate and extent of absorption. Most common adverse reactions in pediatric patients (incidence >2% and greater than rate of placebo) were decreased appetite, headache, insomnia, tic, abdominal pain, vomiting, nausea, irritability, increased heart rate, and blood pressure. Most common adverse reactions (incidence >5% and at least twice the rate of placebo) in adults were decreased appetite, insomnia, dry mouth, diarrhea, nausea, and anxiety. Contraindications to using the patch include taking MAOIs within 14 days as that could lead to a hypertensive crisis. The dextroamphetamine patch has caused Stevens-Johnson Syndrome, angioedema, and urticaria reported on the FDA website without a frequency or method of avoiding.”
Is corrected as
“The amphetamine transdermal system (patch) carries the same warnings as other formulations in the amphetamine class: serious cardiovascular reactions, blood pressure and heart rate increases, psychiatric symptoms including mania and psychosis, suppression of growth, peripheral vasculopathy including Raynaud’s phenomenon, serotonin syndrome, contact sensitization, application site reactions, external heat increases both the rate and extent of absorption. Further, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in post marketing reports of other products in the amphetamine class. Most common adverse reactions in pediatric patients (incidence >2% and greater than rate of placebo) were decreased appetite, headache, insomnia, tic, abdominal pain, vomiting, nausea, irritability, increased heart rate, and blood pressure. Most common adverse reactions (incidence >5% and at least twice the rate of placebo) in adults were decreased appetite, insomnia, dry mouth, diarrhea, nausea, and anxiety. Contraindications to using the patch include taking MAOIs within 14 days as that could lead to a hypertensive crisis.”